FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of ...
A recent study published in Frontiers in Genetics demonstrates that combining copy number variants sequencing (CNVs-seq) and whole exome sequencing (WES) is effective in detecting congenital heart ...
Framingham genetic medicine firm Variantyx has launched a new genome-based test for chromosomal abnormalities. The IriSight CNV Analysis tests for abnormalities potentially causing pregnancy loss or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results